Genmab (CPH:GEN)

FierceBiotech  Mar 27  Comment 
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.
FiercePharma  Oct 4  Comment 
Arzerra has not yet been approved anywhere for a first-line use, but the companies believe that new data will boost its chances. It is asking for it to be used in combination with an alkylator-based therapy in patients for which a...
FiercePharma  Sep 13  Comment 
The FDA will fast-track review of the drug for use with an alkylator-based therapy for the patients with chronic lymphocytic leukaemia (CLL) who have not received any previous treatment and are inappropriate for fludarabine-based therapy.
Benzinga  May 29  Comment 
Genmab A/S and GlaxoSmithKline plc (NYSE: GSK) announced today that their Phase III study of ARZERRA^(R) (ofatumumab) in combination with chlorambucil versus chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia...
FierceBiotech  May 1  Comment 
Eight months after Johnson & Johnson ($JNJ) committed to a $1.1 billion deal package to partner on Genmab's cancer antibody daratumumab, the FDA has blessed the Phase I/II program with its new "breakthrough" designation.   The drug--which...
FierceBiotech  Feb 15  Comment 
Here's more evidence that the biotech industry is giddy about the FDA's new "breakthrough therapy" designation. On speculation that its multiple myeloma contender could get the coveted status, Danish biotech Genmab's shares jumped in trading today...
Wealth Daily  Sep 4  Comment 
Genmab A/S will work with Janssen Biotech to develop an antibody for a cancer molecule...
FierceBiotech  Aug 30  Comment 
Johnson & Johnson isn't known for doing a lot of deals. But when the deal team moves, they do it decisively. That was the case today as J&J ($JNJ) finalized a pact to in-license a promising antibody from Genmab, taking an $80 million equity stake...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki